Brokerages predict that Eagle Pharmaceuticals (NASDAQ:EGRX) will announce earnings per share of $0.96 for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Eagle Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.76 and the highest estimate coming in at $1.16. Eagle Pharmaceuticals posted earnings of $0.49 per share in the same quarter last year, which indicates a positive year over year growth rate of 95.9%. The firm is expected to issue its next earnings report on Wednesday, August 8th.
On average, analysts expect that Eagle Pharmaceuticals will report full-year earnings of $3.31 per share for the current year, with EPS estimates ranging from $3.24 to $3.38. For the next year, analysts forecast that the company will post earnings of $3.88 per share, with EPS estimates ranging from $3.77 to $3.98. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings data on Thursday, May 10th. The specialty pharmaceutical company reported $0.53 earnings per share for the quarter, missing the consensus estimate of $0.68 by ($0.15). The firm had revenue of $46.60 million for the quarter, compared to the consensus estimate of $48.88 million. Eagle Pharmaceuticals had a return on equity of 21.89% and a net margin of 15.32%. The firm’s quarterly revenue was down 39.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.42 EPS.
Several research firms have weighed in on EGRX. BidaskClub cut Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 18th. ValuEngine cut Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Mizuho reiterated a “sell” rating and set a $37.00 price objective on shares of Eagle Pharmaceuticals in a research report on Monday, February 26th. Piper Jaffray reiterated a “buy” rating and set a $79.00 price objective on shares of Eagle Pharmaceuticals in a research report on Tuesday, January 30th. Finally, Royal Bank of Canada set a $71.00 price objective on Eagle Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $63.33.
Eagle Pharmaceuticals traded up $1.73, hitting $67.73, during trading hours on Wednesday, MarketBeat reports. 485,138 shares of the stock were exchanged, compared to its average volume of 240,652. The company has a debt-to-equity ratio of 0.23, a current ratio of 5.87 and a quick ratio of 5.66. The stock has a market capitalization of $957.18 million, a price-to-earnings ratio of 20.10 and a beta of 1.39. Eagle Pharmaceuticals has a 12 month low of $66.89 and a 12 month high of $67.58.
In other news, Director Sander A. Flaum sold 2,340 shares of the stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $53.94, for a total transaction of $126,219.60. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 19.50% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Smith Asset Management Group LP acquired a new stake in shares of Eagle Pharmaceuticals during the 4th quarter worth $187,000. Campbell Newman Asset Management Inc. acquired a new stake in shares of Eagle Pharmaceuticals during the 4th quarter worth $200,000. Matarin Capital Management LLC acquired a new stake in shares of Eagle Pharmaceuticals during the 1st quarter worth $208,000. Jane Street Group LLC acquired a new stake in shares of Eagle Pharmaceuticals during the 1st quarter worth $212,000. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of Eagle Pharmaceuticals during the 4th quarter worth $218,000.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.